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1  | INTRODUC TION
For one and a half decade, tyrosine kinase inhibitors (TKIs) have been 
the standard treatment for Philadelphia chromosome‐positive, BCR‐
ABL1–mutated chronic myeloid leukemia (CML). This story of suc‐
cess had started with the advent of imatinib, the first TKI. In Europe, 
there are now five different TKIs. Three of them, imatinib, dasatinib, 
and nilotinib, can be used as first‐line treatments, while bosutinib 
and ponatinib are only approved as second‐line treatments.
Treatment recommendations suggest the lifelong daily use of 
TKIs for the vast majority of patients.1 However, TKI treatment has 
its price; with about 40 000‐70 000 Euros per patient and year, the 
costs are considerable. Meanwhile, patient protection for imatinib 
has been expired in Germany in 2016 and generic imatinib became 
available.
There is no evidence that elderly patients of 65 years and older 
should not receive TKIs. Recently, Proetel et al2 have shown in a large 
trial that imatinib is effective and well tolerated in all age groups and 
that there is no reason to withhold imatinib from the elderly. Similar 
results had already been published by others.3‐5 Latagliata et al6 
performed a retrospective study on patients older than 75 years, an 
age group often excluded from clinical trials. They concluded as well 
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Abstract
There are established guidelines for treatment and monitoring of chronic myeloid 
leukemia (CML) but little is known about routine care. Data on ICD‐10 codes as well 
as prescribed medications were available for 10.5 million patients in the statutory 
health insurance system in Bavaria for the years 2010 to 2016. Also, data on the 
molecular and cytogenetic monitoring were integrated. A total of 1714 adult patients 
with CML were observed. Only 50.8% received more than 67.5 daily doses per quar‐
ter year (target: 91.5) while 18.2% did not receive any tyrosine kinase inhibitor (TKI). 
The median number of daily doses was at least 80 doses per quarter year for all age 
groups in men, but decreased to 62 doses in elderly women. With this exception, no 
differences between men and women were observed. The percentage of patients 
without any TKI increased with age. The median number of molecular examinations 
was 3.54 independent of age and sex. Even in a highly developed country, still a 
considerable number of patients with CML seem to not receive adequate treatment, 
whereas molecular monitoring can be considered satisfactory.
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that imatinib should be administered to all patients in chronic phase 
regardless of their age. These findings are further confirmed by the 
prognostic EUTOS score, which does not include age as a relevant 
factor for predicting complete cytogenetic remission and progres‐
sion‐free survival.7
An obviously important requirement for an effective treatment 
is that the treatment is used as indicated. Although CML is a fatal 
disease, poor patients' compliance with TKI treatment is common 
and is associated with reduced effectiveness.8‐11 Marin et al, using 
an electronic medication monitoring system, showed that proper ad‐
herence with TKI treatment is a major predictor of achieving major 
molecular remission (MMR) with relative risks between 11.7 and 
17.6.12 A patient can however only be fully compliant if there is a suf‐
ficient supply of medication, that is, if the physician regularly hands 
over a prescription for TKIs.
A regular cytogenetic and/or molecular monitoring has been 
considered necessary for a successful treatment and a prolonged 
survival.13‐15 However, it has been shown that at least in the United 
States, the number of molecular examinations is far away from the 
guidelines' recommendations.16
Thus, the aim of our study was to evaluate whether the prescrib‐
ing of TKIs and the subsequent monitoring of patients with CML in 
Germany follow the current European LeukemiaNet (ELN) recom‐
mendations and whether prescribing is sufficient to allow for a sat‐
isfactory patients' compliance. Notably, we were interested in the 
question, if the prescribing patterns were different between older 
and younger patients and the sexes. Additionally, we wanted to find 
out whether the number of molecular and cytogenetic assessments 
followed the ELN recommendations.
2  | METHODS
The Bavarian Association of Statutory Health Insurance Physicians 
(Kassenärztliche Vereinigung Bayerns, KVB) covers the outpatient 
care of 84% of the Bavarian population of 12.5 million. It holds claims 
data of all bcr‐abl–positive CML diagnoses and prescribed medica‐
tions within the statutory health insurance system with 10.5 million 
people. For our analyses, data from the years 2010 to 2016 were 
used consisting of datasets on a quarterly base. Only patients with 
at least two recordings of CML and a CML‐related treatment (TKI, 
interferon, hydroxyurea, busulfan) in two separate quarters were 
included. The identification of CML cases was done via the ICD‐10 
code C92.1, which represents the code for bcr‐abl–positive CML. 
Details on the identification have already been described else‐
where.17 For all these patients, information on reimbursed, that is, 
handed out, medication was available. As the data are intrinsically 
used for accounting purposes, completeness can be assumed.
All analyses on daily doses of TKIs are based on the dosages 
as approved by the European Medicines Agency (EMA). These 
recommended doses 18‐22 which are identical to the ELN1 recom‐
mended doses can be found in Table 1. These standard dosages are 
the dosages that are reimbursed by the sickness funds without any 
problems. As the dosage for children is calculated according to their 
body surface area,23 we excluded persons below 20 years (n = 4) 
from the analysis.
As there were carried out a few TKI discontinuation trials after 
2012, we performed a sensitivity analysis to account for this. It was 
not possible to identify those patients; thus, the median number of 
TKI doses per quarter year was recalculated after randomly remov‐
ing 20 percent of the quarter years without any TKI admission.
Data on the frequency of cytogenetic evaluations, FISH, and 
PCRs were provided by the Munich Leukemia Laboratory (MLL). The 
MLL is the largest diagnostic laboratory in the field of leukemia and 
lymphomas in Germany and has information on the monitoring of 
about 5000 patients with CML. Data were used from 2010 to 2016 
too. The MLL holds data on all analyses performed there in this time 
frame as well as the date of diagnosis and death, allowing to esti‐
mate the monitoring frequency. It has to be stated that while the 
KVB data represent a complete survey of the Bavarian population 
within the statutory health system, the MLL data represent a sam‐
ple of patients being examined at a specific laboratory. Due to data 
privacy regulations, it was not possible to merge both datasets or to 
link them to any survival data. As, for example, patients without any 
examination can naturally not be part of the MLL dataset, it might be 
seen as a positive selection. Therefore and because of the large sam‐
ple size, no significance tests, that is, no P‐values, were calculated.
All Analyses were performed with R 3.1.0 or SAS 9.4, and figures 
were created with SPSS 22.
3  | RESULTS
3.1 | Tyrosine kinase inhibitors
In total, 2013 different CML patients were identified between 2010 
and 2016 in the KVB data. Of those, 1714 patients were observed 
for more than four quarter years. The number of patients grew from 
1067 in 2011 to 1351 in 2015, indicating a rising prevalence due to 
considerably longer survival times.
During the 6 years analyzed, 1 887 181 daily doses of TKIs, as 
defined in Table 1, had been handed out by pharmacists to patients 
of age 20 and older. The majority of TKI doses were imatinib with 
1 379 515 daily doses (73%), followed by nilotinib with 315 321 daily 
doses (17%) and dasatinib with 185 662 daily doses (10%). These 
drugs were available for the complete observation period. For 
TA B L E  1   Recommended daily doses by the European Medicines 
Agency (EMA) and European LeukemiaNet (ELN) criteria
 Recommended dose
Imatinib 400 mg/d
Dasatinib 100 mg/d
Nilotinib 2 × 300 mg/d
Bosutinib 500 mg/d
Ponatinib 45 mg/d
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ponatinib and bosutinib, only 4133 resp. 2550 daily doses were re‐
corded within the 6 years observed. The low numbers for both are 
not surprising, since both had not been approved before 2013 and 
are second‐line TKIs, only to be prescribed if first‐line TKI had failed.
At first, we analyzed the number of doses prescribed per day. 
By restricting this analysis to patients whose CML was reported for 
at least four subsequent quarter years, we ensured that newly diag‐
nosed patients who were still in their pre‐TKI run‐in phase were not 
considered. Further, this restriction reduces the influence of short‐
term effects.
A total of 1714 patients fulfilled this criterion and were ob‐
served between 2010 and 2016. We identified 311 patients with 
CML (18%) who did not get any TKIs. A total of 135 patients (8%) 
received TKIs but less than 22.5 daily doses per quarter year on 
average, about 25% of the recommended dose. A total of 168 pa‐
tients (10%) received between 22.5 and 45 daily doses and 227 
(13%) more than 45 but less than 67.5 daily doses per quarter. Only 
873 patients (51%) got more than 67.5 daily doses, thereof 61 (4%) 
with more than 100 daily doses per quarter year. The latter are 
likely to be patients that obtained a high‐dose (imatinib) therapy, 
receiving, for example, 600‐800 mg/d. The maximum were 160 
daily doses imatinib per average quarter year. The average daily 
doses per quarter year are shown in detail in Figure 1. A total of 
652 patients received any second‐generation TKI (38.0%). Out of 
the 311 patients that did not receive any TKI, 288 (92.6%) were 
treated with hydroxyurea, and only eight patients (2.6%) received 
interferon.
Table 2 provides an overview across the age groups. When con‐
sidering only those patients that actually had received any TKIs 
in that quarter year, the median number of daily doses was quite 
constant for males with 80 to 85 doses. In contrast, for women we 
observed a slight increase until 50‐59 years from 75 to 83 doses 
per quarter year and a decrease afterward. Women of 80 years and 
above received only 62 daily doses at median per quarter year. The 
details can be found in Figure 2. When taking all patients into ac‐
count, the decrease in the elderly was much stronger.
F I G U R E  1   Histogram of the average 
daily TKI doses per quarter year of the 
1714 patients
 
Number of patients in 
this age group
Observed quarter 
years in this age group
Number of daily doses 
(total) in this age group
Men Women Men Women Men Women
20‐29 31 29 354 334 24 482 17 551
30‐39 65 54 849 618 60 900 36 537
40‐49 153 149 1810 1673 122 716 110 021
50‐59 219 212 2772 2470 198 515 156 543
60‐69 271 277 3088 3473 195 611 216 579
70‐79 345 325 4075 4070 247 533 224 495
80 and older 168 198 1669 2150 75 368 78 963
Note: Naturally, the sum of the patient numbers is larger than the actual number of patients, since 
some patients changed age groups.
TA B L E  2   Overview on the age and sex 
groups
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The percentage of patients who did not receive any TKI increased 
with age with only slight differences between sexes. Between 9% 
and 14% of the patients in the age groups between 20 and 59 did 
not get any TKI, while in the age group 60 to 69 years, already 17% 
of the males and 19% of the females were not treated with any TKI.
This percentage rose to 24% and 25%, respectively, in males and 
females aged between 70 and 79 years, rising further to 31% and 
41% in the oldest age group of 80 years and above.
Looking in detail on the second‐generation TKIs, we found a 
trend toward a more common use over time, while the general use 
of TKI was fairly constant. The percentage of imatinib dropped from 
about 90% of the prescribed TKI doses to 54% in 2016. We did not 
find any differences between men and women regarding the use of 
second‐generation TKI. However, the percentage of patients receiv‐
ing nilotinib decreased with age. While 32% respectively 35% of the 
male resp. female patients between 20 and 29 years received nilo‐
tinib, this was only the case in 11% resp. 15% of the oldest patients. 
For dasatinib, we observed a similar pattern with a maximum of 26% 
resp. 22% of the patients 40 to 49 years and a minimum in the oldest 
age group above 80 years, with only 10% resp. 9%.
Additionally, we performed a sensitivity analysis to account 
for the potential effect of TKI discontinuation trials. The percent‐
age of patients participating in these trials is unknown and cannot 
be estimated from the data. Thus, we identified all those quarter 
years where patients did not receive any TKI or hydroxyurea, but 
had already been receiving TKI before. Per random sampling, 20 
percent of those quarter years were removed. The average dose 
was corrected for those patients. However, the impact on the re‐
sults was only minor. The median increased from 69 to 72 doses 
per quarter year, when considering all patients, and from 77 to 79 
doses per quarter year, when only patients with any TKI admission 
were considered.
3.2 | Cytogenetic and molecular monitoring
Based on the MLL data, we estimated the median number of cytoge‐
netic, FISH, and PCR examinations per patient and year. Only pa‐
tients with at least two examinations and a minimal observation time 
of 1 year were considered. As the differences between Bavaria and 
the rest of Germany were negligible, we report the results for both 
areas taken together. The ELN guidelines recommend that PCRs are 
conducted every 3 months until an MMR has been achieved and 
then every 3 to 6 months. Cytogenetic analyses should be done 
every 3‐6 months until a complete cytogenetic remission has been 
achieved and once per year afterward. Data on 2104 patients were 
used for this analysis.
The median number of cytogenetic examinations in the dataset 
was 0.58 examinations per patient and year, with a slightly higher 
number for male than for female patients (0.61 vs 0.53). When con‐
sidering age groups, we found a trend of decreasing examinations 
with age: While the median in the group 30‐39 years was 0.72 ex‐
aminations per year, only 0.55 were done in patients aged 60‐69 and 
0.44 in the oldest age group (Figure 3). We were not able to find 
any calendar time trend. While the median for patients from office‐
based physicians (OBP) was 0.50 cytogenetic analyses per year, pa‐
tients from municipal hospitals (MH) were examined 0.65 times and 
patients from teaching hospitals (TH) 1.02 times. This difference was 
observed for all age groups.
F I G U R E  2   Median numbers of daily 
TKI doses per quarter year according to 
age group and sex. Please note that the 
youngest age group has been removed 
due to very low patient numbers
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For FISH, the median per patient and year was 0.54 examina‐
tions, with almost no differences between men and women. In con‐
trast to cytogenetics, we did not find any age or other trend as well. 
The differences between treatment centers were smaller, with medi‐
ans of 0.48, 0.62, and 0.74 for OBP, MH, and TH respectively.
The number of PCRs was considerably higher than for both the 
other tests with a median of 3.53 per patient and year. With medi‐
ans of 3.59 and 3.47, we found no considerable differences between 
men and women (Figure 3). 15.6% of the patients received less than 
two PCRs per year, which is the bottom line according to the ELN 
recommendations. When investigating a potential time trend, we 
had to focus on the first year after diagnosis, as the number of exam‐
inations depends on the remission status. Here, we found a steady 
increase with the mean number of PCRs rising from 3.00 in 2010 to 
3.65 in 2015.
For PCR, the treatment center did not seem to play a role, as 
office‐based physicians had even a slightly higher median (3.60) than 
municipal (3.45) and teaching hospitals (3.41).
4  | DISCUSSION
Based on the KVB data, our analyses provide a representative, 
population‐based insight into the current TKI treatment situation. 
That is an important strength of our study. It is alarming that even 
in the most prosperous part of a highly developed country with an 
extensive statutory health insurance system, still a considerable 
number of patients did not receive the adequate treatment for a 
potentially fatal disease. We found that especially elderly patients 
were often treated with hydroxyurea only. But even the patients 
with CML that received TKIs, received on average (at least 30% of 
the population) a too little supply of TKI, did not administer the 
recommended dose of 400 mg imatinib per day. Molecular moni‐
toring was found to be done regularly in the majority of patients 
in all age groups.
The comparison of the numbers estimated from our data to the 
population‐based registry of the European Treatment and Outcome 
Study (EUTOS) 24 for CML is quite interesting. While we found over 
18% of patients not treated with any TKI, this was only the case in 
3% of the patients from the registry. In the EUTOS registry, 80% of 
patients received imatinib as a first‐line treatment and 28% of those 
switched treatment subsequently—mostly to second‐generation 
TKI. This difference may be explained by the year of registration as 
the EUTOS data were collected between 2008 and 2013 when sec‐
ond‐generation TKIs were not yet very common and some had not 
been licensed yet. In the EUTOS data, no significant differences in 
the treatment of males and females were found; the reason may be 
that the EUTOS registry did only ask for prescribed treatment and 
F I G U R E  3   Median number of 
examinations per year according to age 
group and sex
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not for actual dosage used. As in our data, the use of TKIs in the 
EUTOS patients was decreasing in the older age groups.
The percentage of patients not receiving any TKI is considerably 
higher than that published for Sweden,25 where about 94% of the 
patients below 70 years and more than 80% of those above 70 years 
received any TKI in the first year. In contrast to our data, the Swedish 
as well as the EUTOS data refer to newly diagnosed patients only. 
This might at least in part explain the differences.
The withholding of TKI treatment to elderly patients can have 
different reasons. Unfortunately, claims data do not allow analyzing 
causal relations. Elderly patients suffer more frequently from other 
comorbidities, which in some cases can prevent TKI treatment. 
Another reason might be that physicians do not consider it worth‐
while to treat elderly patients with therapies as expensive as TKIs. 
This is sometimes based on a common misunderstanding regarding 
the life expectancy of elderly persons. According to the data of the 
German Federal Statistical Office,26 the current life expectancy of 
a newborn German is 77.72 years for a male and 82.80 years for a 
female. However, if we consider, for example, a 75‐year‐old man, the 
remaining average life expectancy is not just 2.72 but 10.54 years. 
Even an 85‐year‐old man has got a remaining life expectancy of 
5.38 years, a time span that can usually not be reached with a hy‐
droxyurea treatment. One may argue that these are values for 
the normal population, but many studies have shown that today 
patients with CML achieve a life expectancy similar to the normal 
population.2,27‐29
The concept of treatment‐free remission might also be responsi‐
ble for some cases that did not receive a TKI any longer. This discon‐
tinuation of treatment should still be done within prospective clinical 
studies only at the moment, and a few TKI discontinuation trials were 
running in Germany during the time of our study. It is probable that 
in some cases, a discontinuation has been started outside clinical 
trials on the patient's request. It was not possible to identify these 
patients precisely from our data however. But we doubt that there 
were many, in particular not in the early years of our dataset, as the 
first results of the observational STIM study were published late in 
2010 only.30 When we performed a sensitivity analysis assuming a 
very high discontinuation rate of 20 percent, results were rather sim‐
ilar. Furthermore, the number of patients that did not receive any 
TKI should remain unaffected.
For many drugs, differences regarding the pharmacological re‐
sponse between men and women are known.31,32 It has been shown 
for other drugs that women are more likely to have adverse drug 
reactions when getting the same dosage as men due to their lower 
average body weight. Although there are no recommendations for 
weight‐related dose adjustments with regard to TKIs, the differences 
observed here may at least in part be explained by an unintended 
dose adjustment or by a higher tendency to pause the treatment 
after adverse events in women.
However, as recent research showed that actually higher doses 
of imatinib like 600 or 800 mg per day lead to a higher percentage of 
patients in MMR after 12 months of therapy it is alarming that many 
patients actually receive a much lower dose.33,34 In summary, we 
think that our findings re‐access to and intensity of TKI treatment 
deserve further investigations to make sure that all CML patients 
receive optimal treatment.
We found that molecular monitoring was done according to the 
guidelines in the vast majority of patients. Due to their inferior sen‐
sitivity, cytogenetic and FISH analyses have been replaced by mo‐
lecular analyses during the past years. This might be a reason why 
the observed number of cytogenetic analyses is lower than recom‐
mended. These results are in accordance with the work of Geelen 
et al15
Some years ago, we had reported differences in survival be‐
tween teaching hospitals, municipal hospitals, and office‐based phy‐
sicians.35 Here we found differences with regard to cytogenetic but 
not with regard to molecular evaluations. As study compliance may 
be more respected in teaching hospitals, the number of a complete 
examination of bone marrow including chromosome banding anal‐
ysis may be slightly higher in patients referred from those. Further, 
these hospitals might see more higher risk patients that need de‐
tailed diagnostics.
We assume that the results can be generalized to other parts 
of Germany. As Bavaria is one of the most prosperous parts of 
Germany, we do not expect the prescription of TKI to be inferior. 
Further, monitoring frequencies were comparable between Bavaria 
and the rest of Germany.
Like all analyses based on routine data, our study has some lim‐
itations. Naturally, we were not able to see why, for example, a pa‐
tient received a lower dose. In particular, the quarter year structure 
of the data is responsible for small inaccuracies on the individual pa‐
tient's level. However, this should be compensated by the large size 
of the dataset and the long observation period.
The analysis of the monitoring frequencies only covers patients 
whose doctors sent their samples to a specialized laboratory and 
might therefore represent a positive selection. Furthermore, as 
we included only patients that were at least observed for 1 year, 
we missed all those patients that were only monitored at diagno‐
sis. Thus, we are aware that our figures will probably present an 
overestimation.
As it has been repeatedly shown that too low doses of treatment 
with TKIs are accompanied by less therapeutic success, patients 
and physicians need to be motivated to take more care for using 
the required daily dosages. As data indicate, this may even be cost‐
effective as poor adherence with TKI treatment results in higher 
healthcare costs.36
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